TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06011291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2051 tablets
Description: Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2051 tablets
Description: Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2051 tablets
Description: Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Radical or adjuvant radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Radical or adjuvant radiotherapy
Study: NCT04765826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous mini punch grafting
Description: All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous mini punch grafting
Description: All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous mini punch grafting
Description: All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site
Study: NCT05425875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoalveolar lavage using wall mount suction
Description: BAL will be performed using wall mount suction with a pressure \<100 mmHg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage using manual suction
Description: A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage using manual suction with rubber tubing
Description: A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
Study: NCT06513936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The skin care Bundle
Description: S- Secure device and protect the skin with dressings K- Keep repositioning more frequently than twice daily Inspect the skin under the device more than twice daily N- Nutrition and hydration C- Choose the correct size and type of medical device A- Avoid placing devices over sites of prior or existing pressure injury R- Report MDRPI correctly and immediately E- Educate staff on the correct use of devices and prevention of skin breakdown

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine care delivered in the unit
Study: NCT05463432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19024
Description: Intravenous infusion
Study: NCT05323266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (nCPAP)
Description: The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Description: The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
Study: NCT05668468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis IVS-1 capsule
Description: Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
Study: NCT05765370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL
Description: Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C\<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered.
Study: NCT04945772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy Product-MCO-010
Description: The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy Product-MCO-010
Description: The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham Injection
Study: NCT05187299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observer tool
Description: The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
Study: NCT05431595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given by Vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: Given by Vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Given by Vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given by Vein (IV)
Study: NCT05555446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: Subject will receive bovine colostrum with gluten.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive a placebo with gluten.
Study: NCT06077994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital Remote Patient Monitoring+BEPR+ (dRPM+)
Description: In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)
Description: Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
Study: NCT05668468

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cellulose capsule
Description: Daily cellulose capsule
Study: NCT05255588

Intervention type: DEVICE
Intervention: EarlyTect® CRC test
Description: A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
Study: NCT05685667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needless laser injector (Mirajet)
Description: Mirajet injection was performed 2-3 passes until a total of 2cc of diluted PLA/HA solution was completely injected to the one half of the face.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: needle injection
Description: For traditional method of needle injection, intradermal injection using multi-puncture/micro-papule technique was used. A series of injections at 0.5-1 cm apart was performed on one half of the face so that a total of 2cc of diluted PLA/HA solution was injected.
Study: NCT02095236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: organ motion
Description: Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
Study: NCT06191887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BAFFR-targeting CAR T Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy/aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT05765370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
Description: Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C\<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered.
Study: NCT05688644

Intervention type: DEVICE
Intervention: InterStim II
Description: Sacral neuromodulation

Intervention type: DEVICE
Intervention: InterStim II
Description: Sacral neuromodulation
Study: NCT05926258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 3% eye gel
Description: ocular surface anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops
Description: ocular surface anesthesia
Study: NCT05963295

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: toxoplasma igG
Description: Dignosis of toxoplasma

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: toxoplasma igG
Description: Dignosis of toxoplasma
Study: NCT05385497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
Study: NCT05614206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention based on Applied Behavior Analysis principles
Description: Intervention sessions are conducted by licensed therapists with a training in applied behavior analysis or behavior analysts. One-to-one interventions for 3 h/week are carried out over a period of 5 months.~The intervention focused on two target symptoms, imitation and joint attention, as two of the pivotal skills in early development. Behavior analytic techniques are used, including discrete trial, shaping for positive reinforcement, systematic prompting and fading procedures, and reinforcement procedures, according to the published manual.~Imitation sessions start with imitation recognition and imitation of familiar actions (gestural and object imitation) and end with the imitation of novel actions. Joint attention evolvs from initiating requests (starting with gaze shift with the child looking away from an interesting object to the adult and back) to coordination of gaze shift, vocalization and gestures through reaching, and pointing and showing behaviors.
Study: NCT05506553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention arm - Eyhance Toric II Intraocular Lens
Description: Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm - Alcon IQ Toric Intraocular lens
Description: Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
Study: NCT06099691

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
Study: NCT06373042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarterial and intravenous tirofiban
Description: Intraarterial and intravenous tirofiban after endovascular thrombectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraarterial and intravenous placebo
Description: Intraarterial and intravenous placebo after endovascular thrombectomy
Study: NCT05982223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The frequency of acupuncture will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mind-body therapy
Description: The frequency of mind-body therapy (hypnosis, guided imagery) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Touch therapy
Description: The frequency of touch therapy (shiatsu, reflexology) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Movement therapy
Description: The frequency of movement therapy (Tai-Chi, Qi-Qong) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal supplements
Description: The choice of herbal supplement will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
Study: NCT05898074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Absorbable Packing (Silastic Splint)
Description: Participant will have silastic splint applied to nasoseptal flap harvest site
Study: NCT05982223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional treatment
Description: The frequency of emotional treatments (counseling, spiritual guidance) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
Study: NCT05638763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib Pill
Description: Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Pill
Description: Patients will receive ketoconazole 200mg two times a day, orally, for one year.
Study: NCT05696262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-walking program
Description: Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner
Study: NCT05343806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 20 Mg
Description: The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
Study: NCT06326177

Intervention type: PROCEDURE
Intervention: Scapular Dyskinesia
Description: Scapular dyskinesia will be assessed with scapular dyskinesia test. Dumbbells which are 1,5kg will be used in the testing setting. Participant will perform full shoulder abduction for 5 times while examiner assesses the movement quality by ranking it as subtle dyskinesis, obvious dyskinesis and no dyskinesis according to the movement of the scapula. After that participant will perform 5 repetitions of shoulder flexion.
Study: NCT05898074

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PuraGel (RADA16) Hydrogel
Description: Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site